OncoMatch/Clinical Trials/NCT07743944
A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
Is NCT07743944 recruiting? Yes, currently enrolling (Sep 2026).
The study aims to describe demographics, clinical characteristics, genetic test diagnosis, treatment patterns, and clinical outcomes in HR+/HER2- (including HER2-low, HER2-ultralow, and HER2-null) unresectable or metastatic breast cancer patients in China; and exploratory describe clinical outcomes by treatment regimens, also report the QoL and other patient-report outcomes (PRO) and to assess healthcare resource utilization (HCRU) and costs overall and by LoT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression (positive)
HR+ (IHC 2+/ISH- or IHC 1+ or IHC 0, with/without membrane staining)
Required: HER2 (ERBB2) wild-type (negative)
HER2- (IHC 2+/ISH- or IHC 1+ or IHC 0, with/without membrane staining)
Prior therapy
Must have received: systemic therapy — 2L
Planning to initiate 2L treatment or initiated 2L systemic therapy within 2 months prior enrollment as per the prescription or medical records
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07743944 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Does this trial require ESR1?
Yes, ESR1 expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages